CRP and neoplasm: Systemic inflammatory markers—including neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), platelet–lymphocyte ratio (PLR), and C-reactive protein (CRP)—have emerged as accessible prognostic biomarkers, with elevated NLR and CRP correlating with advanced disease and poor outcomes, and altered LMR and PLR reflecting immune status and tumor aggressiveness [97,129,130].